PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD.

Efforts to limit GVHD mediated by alloreactive donor T cells after allogeneic bone marrow transplantation are limited by a concomitant decrease in graft-versus-tumor (GVT) activity and increased possibilities of tumor relapse. Using a novel approach, we adoptively transferred conventional T cells expressing the transcription factor promyelocytic leukemia zinc finger (PLZF), which confers effector properties resembling invariant natural killer T cells, such as copious production of cytokines under suboptimal stimulation. PLZF expression in T-cell allografts attenuates expansion of alloreactive T cells, leading to lower GVHD. Intact alloreactivity-driven antitumor cytokine responses result in preserved GVT effects, leading to improved survival. Our findings suggest that therapy with PLZF-overexpressing T cells would result in overall improved outcomes due to less GVHD and intact GVT effects.

[1]  D. Marin,et al.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. , 2012, Blood.

[2]  C. Anasetti,et al.  Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. , 2011, Blood.

[3]  J. Wolchok,et al.  Altered Development of NKT Cells, γδ T Cells, CD8 T Cells and NK Cells in a PLZF Deficient Patient , 2011, PloS one.

[4]  A. Sepulveda,et al.  Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. , 2011, The Journal of clinical investigation.

[5]  A. Luster,et al.  PLZF induces an intravascular surveillance program mediated by long-lived LFA-1–ICAM-1 interactions , 2011, The Journal of experimental medicine.

[6]  Michael G. Constantinides,et al.  Promyelocytic Leukemia Zinc Finger Turns on the Effector T Cell Program without Requirement for Agonist TCR Signaling , 2011, The Journal of Immunology.

[7]  M. Shlomchik,et al.  A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. , 2011, Blood.

[8]  R. Luong,et al.  Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. , 2011, Blood.

[9]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[10]  W. Leonard,et al.  Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. , 2010, Blood.

[11]  B. McColl,et al.  Interleukin-1 drives cerebrovascular inflammation via MAP kinase-independent pathways. , 2010, Current neurovascular research.

[12]  Christopher G. King,et al.  Absence of P-Selectin in Recipients of Allogeneic Bone Marrow Transplantation Ameliorates Experimental Graft-versus-Host Disease , 2010, The Journal of Immunology.

[13]  K. Nichols,et al.  PLZF Induces the Spontaneous Acquisition of Memory/Effector Functions in T Cells Independently of NKT Cell-Related Signals , 2010, The Journal of Immunology.

[14]  R. Jenq,et al.  Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer , 2010, Nature Reviews Cancer.

[15]  T. Yi,et al.  T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  K. Welte,et al.  Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. , 2009, Blood.

[17]  Lieping Chen,et al.  Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. , 2009, Blood.

[18]  Christopher G. King,et al.  IL-17 contributes to CD4-mediated graft-versus-host disease. , 2009, Blood.

[19]  Christopher G. King,et al.  STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. , 2008, Blood.

[20]  T. Rülicke,et al.  The transcriptional regulator PLZF induces the development of CD44 high memory phenotype T cells , 2008, Proceedings of the National Academy of Sciences.

[21]  O. Lantz,et al.  The transcription factor PLZF directs the effector program of the NKT cell lineage. , 2008, Immunity.

[22]  P. Pandolfi,et al.  The BTB–zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions , 2008, Nature Immunology.

[23]  C. Klein,et al.  Cytotoxic T Cells Reactive to an Immunodominant Leukemia-associated Antigen can be Specifically Primed and Expanded by Combining a Specific Priming Step With Nonspecific Large-scale Expansion , 2008, Journal of immunotherapy.

[24]  M. V. D. van den Brink,et al.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. , 2006, Blood.

[25]  M. V. D. van den Brink,et al.  CCR2 is required for CD8-induced graft-versus-host disease. , 2005, Blood.

[26]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[27]  M. V. D. van den Brink,et al.  Fas-Deficient lpr Mice Are More Susceptible to Graft-Versus-Host Disease1 , 2000, The Journal of Immunology.

[28]  K. Oshimi,et al.  Differential Effects of Anti-Fas Ligand and Anti-Tumor Necrosis Factor α Antibodies on Acute Graft-Versus-Host Disease Pathologies , 1998 .

[29]  K. Oshimi,et al.  Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. , 1998, Blood.